Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Methylation‑associated silencing of miR‑128 promotes the development of esophageal cancer by targeting COX‑2 in areas with a high incidence of esophageal cancer.
|
30535495 |
2019 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province.
|
29893307 |
2018 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Thus, this meta-analysis was conducted to comprehensively evaluate the impact of COX-2 expression on the prognostic value in patients with EC.
|
28652771 |
2017 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In the present study, we demonstrated that celecoxib antagonized oxaliplatin-induced cytotoxicity and apoptosis independent of COX-2 inhibition in human esophageal cancer cells.
|
26474693 |
2016 |
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We performed a gene-wide tag SNP-based association study to examine the association of SNPs in PTGS2 and PLA2G2A with ESCC in 269 patients and 269 healthy controls from Taihangshan Mountain, Henan and Hebei Provinces, the rural area of China which has the highest incidence of esophageal cancer in the world.
|
24641411 |
2014 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Furthermore, treatment of siRNA for APE-1 significantly reduced COX-2 expression and VEGF production in MCP-1-stimulated esophageal cancer cell lines.
|
24284961 |
2014 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
RGD |
Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma.
|
22165968 |
2012 |
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A large number of studies have demonstrated a strong association between COX-2 polymorphisms and EC risk.
|
21304218 |
2011 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The esophageal cancer cell lines (EC9706) that express COX-2 permanently and hepatocellular carcinoma cell lines (SMMC7721) while no expression of COX-2 were studied.
|
18443952 |
2008 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Esophageal tissue with a positive expression of p53 or COX-2 was more likely to develop esophageal cancer.
|
17650224 |
2007 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
|
17511025 |
2007 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
|
17707579 |
2007 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
We analyzed the association of COX-2 mRNA and protein expression with histomorphologic response to neoadjuvant radiochemotherapy in esophageal cancer.
|
16322294 |
2005 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The association of several clinicopathological parameters with the immunohistochemical expression of COX-2 was analyzed in paraffin-embedded esophageal cancer specimens.
|
15978332 |
2005 |
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These findings indicate that genetic variants in COX-2 may play a role in mediating susceptibility to esophageal cancer.
|
16083713 |
2005 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We analyzed the association of COX-2 mRNA and protein expression with histomorphologic response to neoadjuvant radiochemotherapy in esophageal cancer.
|
16322294 |
2005 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Up-regulation of COX-2 mRNA and protein was observed in esophageal cancer cells transfected with heparanase cDNA.
|
16299228 |
2005 |
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
These findings indicate that genetic variants in COX-2 may play a role in mediating susceptibility to esophageal cancer.
|
16083713 |
2005 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
|
15151617 |
2004 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
These results suggest that COX-2 may be an important factor for esophageal cancer and inhibition of COX-2 may be helpful for prevention and possibly treatment of this cancer.
|
15259059 |
2004 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
These results suggest that COX-2 may be an important factor for esophageal cancer and inhibition of COX-2 may be helpful for prevention and possibly treatment of this cancer.
|
15259059 |
2004 |
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells.
|
11821953 |
2002 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
NS398 decreased cell viability in 2 cyclo-oxygenase-2-positive (COX-2(+)) esophageal cancer cell lines but not in a COX-2(-) cell line.
|
11410869 |
2001 |
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
|
11059772 |
2000 |